Danai Dima
@DimaDanai
Followers
453
Following
3K
Media
1
Statuses
304
Assistant Professor UW, FHCC, Hematologist
Joined July 2021
As am departing from an amazing experience in Brazil with 4 cities & amazing colleagues, I prepared for a fun SPS meeting in Seattle Oct 4-5, link is below: https://t.co/P1rfcxhEdZ
@fredhutch @CParkMD @VenurVyshak @mshadman @DimaDanai @easterho @spsutkaMD @HsiehLab @DrOmarMian
2
4
25
Happy Saturday! This weekend, catch up on the latest episodes of The HemOnc Pulse with @andrewbrunner, @GKaurMD, @DimaDanai, @LymphClinician, and many more! 🎧 https://t.co/rWvDmrl8IA
1
2
5
Academic medicine is bleeding talent. The best experts are counting to retire or switch careers at an alarming rate. It’s folly to think that you can replace top talent easily — you will need 10 people to provide the level of productivity of one top talent. The effects may
16
33
228
I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇 https://t.co/3oDrO4k96j 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS
1
22
59
Grateful to all the amazing faculty who’ve joined us in Bermuda this week! 🏝️ #DAVAHeme has been energizing so far, two impactful days of science, collaboration, and big ideas. Can’t wait for three more days of shaping the future of hematologic malignancies care.
0
9
29
🚀 Excited to kick off our 2025 Bermuda Hematologic Malignancies Summit! 🎉 Join us as we dive into a packed agenda filled with insightful discussions. Practicing HCPs are welcome to join in through our virtual platform! https://t.co/TkpiJMvXo5
#DAVAHeme
0
2
15
This is re(n)ally awesome!!! Well-written guidelines re: kidney transplant in myeloma et al by tour de force team: @vsanchorawala @LandauHeather #nelsonleung et al. Nice figures for #MMsm (stratify by 🐠 & MRD), MGUS, and SMM below. 🚨 MRD-neg *not* needed if standard risk.
Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. - Aim for good disease control in standard-risk myeloma - Aim for MRD negativity in high-risk myeloma - Avoid IMiDs after transplant if possible - Reduce immunosuppression
1
12
40
In this Editor’s Special Episode of The HemOnc Pulse, @GKaurMD (@MountSinaiNYC) and @DimaDanai (@fredhutch) explore the most promising investigational and newly approved therapies for patients with relapsed or refractory multiple #myeloma. 🎧 Listen here! https://t.co/DhzOdjpsmD
0
5
10
Come work with us!! cc @MadhavDhodapkar @AJPortuguese @DimaDanai @RichaThakurMD and many more not on Twitter!
Fred Hutch is seeking a clinician-scholar committed to advancing leading-edge research and delivering world-class treatment in #multiplemyeloma and related plasma cell disorders. Learn more and apply: https://t.co/A8kzeCVaap
#MMsm
2
11
34
🚀 Excited to unveil the agenda for the 2025 DAVA Bermuda Summit on Hematologic Malignancies.🌟 #DAVAHeme will cover the latest data and emerging strategies in multiple myeloma, leukemia, MDS, MPN, and lymphoma. Check out our website! https://t.co/gzLezogBXn
0
5
16
Join @CParkMD & me on Dec 13 in Seattle for a fantastic Master Lectures series with stellar speakers, interactions, fun! Register below: https://t.co/c1MfXdBKp9
@PavlosMsaouel @mshadman @RahulBanerjeeMD @DRBakaloudiMD @DMakrakisMD @HsiehLab @DimaDanai @fredhutch @DrOmarMian
1
9
18
Shocker for me. ODAC votes against belantamab risk benefit for myeloma. I hope that this vote reflects the way the questions were narrowly worded. I still hope the drug still gets FDA approved.
9
8
57
2/ Another great publication by US Myeloma Immunotherapy Consortium, this one led by @BeaRazzo @AlGarfall 👏 Adding @SurbhiSidanaMD @DrKrinaPatel #dorishansen @DimaDanai @AJPortuguese @GKaurMD @ldandersonjr @YiLinMDPhD @cjferreriMD @PlasmaCellPete @leshune and many more!
0
2
10
Phenomenal 2nd day @binaytara Best of @ASCO with interactions with colleagues/friends in broader community! Stellar speakers & team based learning! @binayshah @nicoleflemingmd @fredhutch @mshadman @LeiDeng3 @DrDianeTseng @HibaMKhanMD @LisaTachiki @easterho @ronanhsieh @HsiehLab
Fantastic day 1 in @binaytara Best of @ASCO in Seattle with great speakers, discussions, Q&A: Interactive & fun, also with Greek mythology :-) @fredhutch @nicoleflemingmd @binayshah @chiragshahmd @VenurVyshak @LisaTachiki @DimaDanai @ronanhsieh @mshadman @HsiehLab @LeiDeng3
1
8
26
Fantastic day 1 in @binaytara Best of @ASCO in Seattle with great speakers, discussions, Q&A: Interactive & fun, also with Greek mythology :-) @fredhutch @nicoleflemingmd @binayshah @chiragshahmd @VenurVyshak @LisaTachiki @DimaDanai @ronanhsieh @mshadman @HsiehLab @LeiDeng3
3
8
47
It's the last day of @ASCO #ASCO25 and the last day of #OntheClock ⏱️ with MedNews Week. In this clip, MinhTri Nguyen, MD, of @StanfordHealth, discusses the SERENA6 data with @YLeyfman Did he beat the clock? 👀
2
6
11
Thank you to @SurbhiSidanaMD of @StanfordMed discussed the CARTITUDE-4 survival subgroup analyses with cilta-cel in relapsed/refractory multiple myeloma! Visit https://t.co/E5LOd0oiTe to learn more about this and many other studies at #ASCO25. #oncology #mmsm
1
2
29
So excited to share that my piece on Unmet Palliative Care Needs in Patients with Multiple Myeloma was featured in Hematopoiesis @ASH_hematology. Huge thank you to @AgrimaMianMD and @CarrawayHetty for their help and support as well as all of my incredible mentors! #MMSM #PallOnc
3
6
26
Thank you again to @mmejia91 @WeillCornell for this very kind invitation! I love getting to use all my hashtags in a single presentation: #downwithdex, #topeeornottopee and more while talking about myeloma. More work to be done here for sure!
@RahulBanerjeeMD teaching us the "p value of pee", #downwithdex, and other "less is more approaches" in #mmsm at @WeillCornell hem/onc grand rounds...as always, great speaker and very compelling data for day-to-day use
1
2
14